Global and national trends in the evolution of infective endocarditis

For the recent 20 years, substantial changes have occurred in all aspects of infectious endocarditis (IE), the evolution of risk factors, modernization of diagnostic methods, therapeutic and preventive approaches. The global trends are characterized by increased IE morbidity among people older than 65 who use intravenous psychoactive drugs. The epidemiological trend is represented by reduced roles of chronic rheumatic heart disease and congenital heart defects, increased proportion of IE associated with medical care, valve replacement, installation of intracardiac devices, and increased contribution of Staphylococcus spp. and Enterococcus spp. to the IE etiology. Additional visualization methods (fluorodeoxyglucose positron emission tomography with 18F-fludesoxyglucose (18F-FDG PET-CT), labeled white blood cell single-photon emission computed tomography (SPECT), and modernization of the etiological diagnostic algorithm for determining the true pathogen (immunochemistry, polymerase chain reaction, sequencing) also become increasingly important. The COVID-19 pandemic has also adversely contributed to the IE epidemiology. New prospects of treatment have emerged, such as bacteriophages, lysins, oral antibacterial therapy, minimally invasive surgical strategies (percutaneous mechanical aspiration), endovascular mechanical embolectomy. The physicians’ compliance with clinical guidelines (CG) is low, which contributes to the high rate of adverse outcomes of IE, while simple adherence to the CG together with more frequent use of surgical treatment doubles survival. Systematic adherence to CG, timely prevention and implementation of the Endocarditis Team into practice play the decisive role in a favorable prognosis of dynamically changing IE. This article presents the authors’ own data that confirm the evolutionary trends of current IE.

1. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. Journal of the American College of Cardiology. 2020;76(25):2982–3021. DOI: 10.1016/j.jacc.2020.11.010

2. Yang X, Chen H, Zhang D, Shen L, An G, Zhao S. Global magnitude and temporal trend of infective endocarditis, 1990–2019: results from the Global Burden of Disease Study. European Journal of Preventive Cardiology. 2022;29(8):1277–86. DOI: 10.1093/eurjpc/zwab184

3. Federal State Statistics Service. Operational demographic indicators. 2020. Av. at: https://rosstat.gov.ru/storage/mediabank/ BgjLrP31/demogr_01-06.pdf.

4. Lindner D, Fitzek A, Brauninger H, Aleshcheva G, Edler C, Meissner K et al. Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. JAMA Cardiology. 2020;5(11):1281–5. DOI: 10.1001/jamacardio.2020.3551

5. Kumanayaka D, Mutyala M, Reddy DV, Slim J. Coronavirus Disease 2019 Infection as a Risk Factor for Infective Endocarditis. Cureus. 2021;13(5):e14813. DOI: 10.7759/cureus.14813

6. Sanghavi DK, Titus A, Caulfield TR, David Freeman W. Endotheliitis, endothelin, and endothelin receptor blockers in COVID-19. Medical Hypotheses. 2021; 150:110564. DOI: 10.1016/j.mehy.2021.110564

7. Benmalek R, Mechal H, Choukrallah H, Maaroufi A, Benouna EG, Habbal R et al. Bacterial co-infections and superinfections in COVID-19: a case report of right heart infective endocarditis and literature review. Pan African Medical Journal. 2020;35(Suppl 2):40. DOI: 10.11604/pamj.supp.2020.35.2.23577

8. Regazzoni V, Loffi M, Garini A, Danzi GB. Glucocorticoid-Induced Bacterial Endocarditis in COVID-19 Pneumonia – Something to Be Concerned About? Circulation Journal. 2020;84(10):1887. DOI: 10.1253/circj.CJ-20-0462

9. Cosyns B, Motoc A, Arregle F, Habib G. A Plea Not to Forget Infective Endocarditis in COVID-19 Era. JACC: Cardiovascular Imaging. 2020;13(11):2470–1. DOI: 10.1016/j.jcmg.2020.07.027

10. Schizas N, Michailidis T, Samiotis I, Patris V, Papakonstantinou K, Argiriou M et al. Delayed Diagnosis and Treatment of a Critically Ill Patient with Infective Endocarditis Due to a False-Positive Molecular Diagnostic Test for SARS-CoV-2. American Journal of Case Reports. 2020;21:e925931. DOI: 10.12659/AJCR.925931

11. Pommier T, Benzenine E, Bernard C, Mariet A-S, Béjot Y, Giroud M et al. Trends of Myocarditis and Endocarditis Cases before, during, and after the First Complete COVID-19-Related Lockdown in 2020 in France. Biomedicines. 2022;10(6):1231. DOI: 10.3390/biomedicines10061231

12. Havers-Borgersen E, Fosbol EL, Butt JH, Petersen JK, Dalsgaard A, Kyhl F et al. Incidence of infective endocarditis during the coronavirus disease 2019 pandemic: A nationwide study. IJC Heart & Vasculature. 2020;31:100675. DOI: 10.1016/j.ijcha.2020.100675

13. Noubiap JJ, Nkeck JR, Kwondom BS, Nyaga UF. Epidemiology of infective endocarditis in Africa: a systematic review and meta-analysis. The Lancet Global Health. 2022;10(1):e77–86. DOI: 10.1016/S2214-109X(21)00400-9

14. Urina-Jassir M, Jaimes-Reyes MA, Martinez-Vernaza S, Quiroga-Vergara C, Urina-Triana M. Clinical, Microbiological, and Imaging Characteristics of Infective Endocarditis in Latin America: A Systematic Review. International Journal of Infectious Diseases. 2022;117:312–21. DOI: 10.1016/j.ijid.2022.02.022

15. Kumar RK, Antunes MJ, Beaton A, Mirabel M, Nkomo VT, Okello E et al. Contemporary Diagnosis and Management of Rheumatic Heart Disease: Implications for Closing the Gap: A Scientific Statement From the American Heart Association. Circulation. 2020;142(20):e337–57. DOI: 10.1161/CIR.0000000000000921

16. Watkins DA, Johnson CO, Colquhoun SM, Karthikeyan G, Beaton A, Bukhman G et al. Global, Regional, and National Burden of Rheumatic Heart Disease, 1990–2015. New England Journal of Medicine. 2017;377(8):713–22. DOI: 10.1056/NEJMoa1603693

17. Torbica A, Banks H, Valzania C, Boriani G, Fattore G. Investigating Regional Variation of Cardiac Implantable Electrical Device Implant Rates in European Healthcare Systems: What Drives Differences? Health Economics. 2017;26(1):30–45. DOI: 10.1002/hec.3470

18. Jensen AD, Bundgaard H, Butt JH, Bruun NE, Voldstedlund M, Torp-Pedersen C et al. Temporal changes in the incidence of infective endocarditis in Denmark 1997–2017: A nationwide study. International Journal of Cardiology. 2021; 326:145–52. DOI: 10.1016/j.ijcard.2020.10.029

19. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta J-P, Del Zotti F et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC)Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). European Heart Journal. 2015;36(44):3075–128. DOI: 10.1093/eurheartj/ehv319

20. Demin A.A., Kobalava Zh.D., Skopin I.I., Tyurin P.V., Boytsov S.A., Golukhova E.Z. et al. Infectious endocarditis and infection of intracardiac devices in adults. Clinical guidelines 2021. Russian Journal of Cardiology. 2022;27(10):113–92. DOI: 10.15829/1560-4071-2022-5233

21. Ostergaard L, Valeur N, Ihlemann N, Smerup MH, Bundgaard H, Gislason G et al. Incidence and factors associated with infective endocarditis in patients undergoing left-sided heart valve replacement. European Heart Journal. 2018;39(28):2668–75. DOI: 10.1093/eurheartj/ehy153

22. Moiseev V.S., Kobalava Zh.D., Pisaryuk A.S., Milto A.S., Kotova E.O., Karaulova Yu.L. et al. Infective Endocarditis in Moscow General Hospital: Clinical Characteristics and Outcomes (Single-Center 7 Years’ Experience). Kardiologiia. 2018;58(12):66–75. DOI: 10.18087/cardio.2018.12.10192

23. Chipigina N.S., Karpova N.Yu., Anichkov D.A., Kondratieva T.B. Infectious Endocarditis in the Elderly – Comparative Study of Clinical Features, Course and Outcomes. Rational Pharmacotherapy in Cardiology. 2020;16(2):166–74. DOI: 10.20996/1819-6446-2020-03-02

24. Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M et al. Prevention of Infective Endocarditis: Guidelines From the American Heart Association: A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007;116(15):1736–54. DOI: 10.1161/CIRCULATIONAHA.106.183095

25. NICE. Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures. Clinical guideline [CG64]. 2008. PMID: 21656971. [Internet] Available at: https://www.nice.org.uk/guidance/CG64

26. DeSimone DC, Tleyjeh IM, Correa de Sa DD, Anavekar NS, Lahr BD, Sohail MR et al. Incidence of Infective Endocarditis Due to Viridans Group Streptococci Before and After the 2007 American Heart Association’s Prevention Guidelines: an extended evaluation of the Olmsted County, Minnesota, population and Nationwide Inpatient Sample. Mayo Clinic Proceedings. 2015;90(7):874–81. DOI: 10.1016/j.mayocp.2015.04.019

27. Habib G, Erba PA, Iung B, Donal E, Cosyns B, Laroche C et al. Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. European Heart Journal. 2019;40(39):3222–32. DOI: 10.1093/eurheartj/ehz620

28. Anguita P, Castillo JC, López-Aguilera J, Herrera M, Pan M, Anguita M. Changes in the microbiological etiology of infective endocarditis in our region in the last 3 decades (1987-2019). Revista Espanola de Cardiologia (English Edition). 2021;74(3):272–5. DOI: 10.1016/j.rec.2020.06.037

29. Escolà-Vergé L, Fernández-Hidalgo N, Larrosa MN, Fernandez-Galera R, Almirante B. Secular trends in the epidemiology and clinical characteristics of Enterococcus faecalis infective endocarditis at a referral center (2007–2018). European Journal of Clinical Microbiology & Infectious Diseases. 2021;40(6):1137–48. DOI: 10.1007/s10096-020-04117-x

30. Giannitsioti E, Pefanis A, Gogos C, Lekkou A, Dalekos GN, Gatselis N et al. Evolution of epidemiological characteristics of infective endocarditis in Greece. International Journal of Infectious Diseases. 2021;106:213–20. DOI: 10.1016/j.ijid.2021.03.009

31. Habib G, Hoen B, Tornos P, Thuny F, Prendergast B, Vilacosta I et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. European Heart Journal. 2009;30(19):2369–413. DOI: 10.1093/eurheartj/ehp285

32. Kotova E.O., Domonova E.A., Karaulova Yu.L., Milto A.S., Pisaryuk A.S., Silveistrova O.Yu. et al. Infective endocarditis: Importance of molecular biological techniques in etiological diagnosis. Therapeutic Archive. 2016;88(11):62–7. DOI: 10.17116/terarkh2016881162-67

33. Kotova E.O., Domonova E.A., Kobalava Zh.D., Shipulina O.Yu., Karaulova Yu.L., Pisaryuk A.S. Infective Endocarditis with Unknown Etiology: Possibilities of Conquering and Role of Microbiologistics. Kardiologiia. 2021;61(1):87–97. DOI: 10.18087/cardio.2021.1.n1218

34. Baddour LM, Wilson WR, Bayer AS, Fowler VG, Tleyjeh IM, Rybak MJ et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2015;132(15):1435–86. DOI: 10.1161/CIR.0000000000000296

35. Aslanidi I.P., Golukhova E.Z., Pursanova D.M., Mukhortova O.V., Shurupova I.V., Ekaeva I.V. et al. Analysis of factors affecting the accuracy of 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography in case of suspected prosthetic valve infective endocarditis. Russian Journal of Cardiology. 2021;26(12):32–9. DOI: 10.15829/1560-4071-2021-4764

36. Mahmood M, Kendi AT, Ajmal S, Farid S, O’Horo JC, Chareonthaitawee P et al. Meta-analysis of 18F-FDG PET/CT in the diagnosis of infective endocarditis. Journal of Nuclear Cardiology. 2019;26(3):922–35. DOI: 10.1007/s12350-017-1092-8

37. Mikail N, Hyafil F. Nuclear Imaging in Infective Endocarditis. Pharmaceuticals. 2021;15(1):14. DOI: 10.3390/ph15010014

38. Boils CL, Nasr SH, Walker PD, Couser WG, Larsen CP. Update on endocarditis-associated glomerulonephritis. Kidney International. 2015;87(6):1241–9. DOI: 10.1038/ki.2014.424

39. Conlon PJ, Jefferies F, Krigman HR, Corey GR, Sexton DJ, Abramson MA. Predictors of prognosis and risk of acute renal failure in bacterial endocarditis. Clinical Nephrology. 1998;49(2):96–101. PMID: 9524779

40. Pisaryuk A, Povalyaev N, Sorokina M, Balatskiy A, Kotova E, Karaulova Y et al. SP246. Prevalence, clinical features and outcomes of acute kidney disease in infective endocarditis. Nephrology Dialysis Transplantation. 2019;34(Suppl 1):gfz103.SP246. DOI: 10.1093/ndt/gfz103.SP246

41. Povalyaev N, Pisaryuk A, Sorokina M, Teterina M, Balatskiy A, Belomyttsev S et al. 3329. Renal pathologic findings and clinical associations in patients with infective endocarditis. European Heart Journal. 2019;40(Suppl 1):ehz745.0081. DOI: 10.1093/eurheartj/ ehz745.0081

42. Pisaryuk A.S., Zamarashkina V.A., Safarova N.B., Povalyaev N.M., Kotova E.O., Babukhina Yu.I. et al. Coagulation Disorders in Infective Endocarditis: Role of Pathogens, Biomarkers, Antithrombotic Therapy (Systematic Review). Rational Pharmacotherapy in Cardiology. 2022;18(3):320–31. DOI: 10.20996/1819-6446-2022-06-14

43. Yucel E, Bearnot B, Paras ML, Zern EK, Dudzinski DM, Soong C-P et al. Diagnosis and Management of Infective Endocarditis in People Who Inject Drugs: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2022;79(20):2037–57. DOI: 10.1016/j.jacc.2022.03.349

44. Huang G, Davis KA, Petty SA, Tan WA, Barnes EW, Peacock JE. Leftsided infective endocarditis in persons who inject drugs. Infection. 2020; 48(3):375–83. DOI: 10.1007/s15010-020-01402-x

45. Pericas JM, Llopis J, Athan E, Hernandez-Meneses M, Hannan MM, Murdoch DR et al. Prospective Cohort Study of Infective Endocarditis in People Who Inject Drugs. Journal of the American College of Cardiology. 2021;77(5):544–55. DOI: 10.1016/j.jacc.2020.11.062

46. Kaura A, Byrne J, Fife A, Deshpande R, Baghai M, Gunning M et al. Inception of the ‘endocarditis team’ is associated with improved survival in patients with infective endocarditis who are managed medically: findings from a before-and-after study. Open Heart. 2017;4(2):e000699. DOI: 10.1136/openhrt-2017-000699

47. Ruch Y, Mazzucotelli J-P, Lefebvre F, Martin A, Lefebvre N, Douiri N et al. Impact of Setting up an “Endocarditis Team” on the Management of Infective Endocarditis. Open Forum Infectious Diseases. 2019;6(9):ofz308. DOI: 10.1093/ofid/ofz308

48. Weimer MB, Falker CG, Seval N, Golden M, Hull SC, Geirsson A et al. The Need for Multidisciplinary Hospital Teams for Injection Drug Use-related Infective Endocarditis. Journal of Addiction Medicine. 2022;16(4):375–8. DOI: 10.1097/ADM.0000000000000916

49. Vatutin N.T., Taradin G.G., Tchaus E.A., Smirnova A.S. Infective endocarditis in elderly: from etiology to treatment and prevention. Russian Journal of Cardiology. 2016;21(1):80–9. DOI: 10.15829/1560-4071-2016-1-80-89

50. Ursi MP, Durante Mangoni E, Rajani R, Hancock J, Chambers JB, Prendergast B. Infective Endocarditis in the Elderly: Diagnostic and Treatment Options. Drugs & Aging. 2019;36(2):115–24. DOI: 10.1007/s40266-018-0614-7

51. Lomas JM, Martinez-Marcos FJ, Plata A, Ivanova R, Galvez J, Ruiz J et al. Healthcare-associated infective endocarditis: an undesirable effect of healthcare universalization. Clinical Microbiology and Infection. 2010;16(11):1683–90. DOI: 10.1111/j.1469-0691.2010.03043.x

52. Yang F, Zhang B, Yu J, Shao L, Zhou P, Zhu L et al. Epidemiology and the prognosis of healthcare–associated infective endocarditis in China: the significance of non-nosocomial acquisition. Emerging Microbes & Infections. 2015;4(1):1–6. DOI: 10.1038/emi.2015.38

53. Heldman AW, Hartert TV, Ray SC, Daoud EG, Kowalski TE, Pompili VJ et al. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: Prospective randomized comparison with parenteral therapy. The American Journal of Medicine. 1996;101(1):68–76. DOI: 10.1016/S0002-9343(96)00070-8

54. Iversen K, Ihlemann N, Gill SU, Madsen T, Elming H, Jensen KT et al. Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis. New England Journal of Medicine. 2019;380(5):415–24. DOI: 10.1056/NEJMoa1808312

55. Pries-Heje MM, Wiingaard C, Ihlemann N, Gill SU, Bruun NE, Elming H et al. Five-Year Outcomes of the Partial Oral Treatment of Endocarditis (POET) Trial. New England Journal of Medicine. 2022;386(6):601–2. DOI: 10.1056/NEJMc2114046

56. Gilbey T, Ho J, Cooley LA, Petrovic Fabijan A, Iredell JR. Adjunctive bacteriophage therapy for prosthetic valve endocarditis due to Staphylococcus aureus. Medical Journal of Australia. 2019;211(3):142-143.e1. DOI: 10.5694/mja2.50274

57. Petrovic Fabijan A, Lin RCY, Ho J, Maddocks S, Ben Zakour NL, Iredell JR et al. Safety of bacteriophage therapy in severe Staphylococcus aureus infection. Nature Microbiology. 2020;5(3):465–72. DOI: 10.1038/s41564-019-0634-z

58. Fowler VG, Das AF, Lipka-Diamond J, Schuch R, Pomerantz R, Jauregui-Peredo L et al. Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis. Journal of Clinical Investigation. 2020;130(7):3750–60. DOI: 10.1172/JCI136577

59. Eisen DP, McBryde ES. An Association Between Aspirin Use in Human Cases of Infective Endocarditis and Reduced Systemic Embolism Is Shown in Meta-analysis of Observational Studies. Journal of Infectious Diseases. 2015;212(4):673–4. DOI: 10.1093/infdis/jiv131

60. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Fleisher LA et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease. Journal of the American College of Cardiology. 2017;70(2):252–89. DOI: 10.1016/j.jacc.2017.03.011

61. George B, Voelkel A, Kotter J, Leventhal A, Gurley J. A novel approach to percutaneous removal of large tricuspid valve vegetations using suction filtration and veno-venous bypass: A single center experience. Catheterization and Cardiovascular Interventions. 2017;90(6):1009–15. DOI: 10.1002/ccd.27097

62. Moriarty JM, Rueda V, Liao M, Kim GHJ, Rochon PJ, Zayed MA et al. Endovascular Removal of Thrombus and Right Heart Masses Using the AngioVac System: Results of 234 Patients from the Prospective, Multicenter Registry of AngioVac Procedures in Detail (RAPID). Journal of Vascular and Interventional Radiology. 2021;32(4):549-557.e3. DOI: 10.1016/j.jvir.2020.09.012

63. Zern EK, Ramirez PR, Rubin J, Rosenfield K, Manning P, Raz Y et al. Severe Tricuspid Valve Endocarditis: a tale of 2 circuits. JACC: Case Reports. 2021;3(11):1343–9. DOI: 10.1016/j.jaccas.2021.06.023

64. Han H-C, Hawkins NM, Pearman CM, Birnie DH, Krahn AD. Epidemiology of cardiac implantable electronic device infections: incidence and risk factors. EP Europace. 2021;23(Suppl 4):iv3–10. DOI: 10.1093/europace/euab042

65. Asundi A, Stanislawski M, Mehta P, Baron AE, Mull HJ, Ho PM et al. Real-world effectiveness of infection prevention interventions for reducing procedure-related cardiac device infections: Insights from the veterans affairs clinical assessment reporting and tracking program. Infection Control & Hospital Epidemiology. 2019;40(8):855–62. DOI: 10.1017/ice.2019.127

66. Kewcharoen J, Kanitsoraphan C, Thangjui S, Leesutipornchai T, Saowapa S, Pokawattana A et al. Postimplantation pocket hematoma increases risk of cardiac implantable electronic device infection: A meta?analysis. Journal of Arrhythmia. 2021;37(3):635–44. DOI: 10.1002/joa3.12516

67. El-Chami MF, Bonner M, Holbrook R, Stromberg K, Mayotte J, Molan A et al. Leadless pacemakers reduce risk of device-related infection: Review of the potential mechanisms. Heart Rhythm. 2020;17(8):1393–7. DOI: 10.1016/j.hrthm.2020.03.019

68. Ozaki S, Kawase I, Yamashita H, Uchida S, Takatoh M, Kiyohara N. Midterm outcomes after aortic valve neocuspidization with glutaraldehyde-treated autologous pericardium. The Journal of Thoracic and Cardiovascular Surgery. 2018;155(6):2379–87. DOI: 10.1016/j.jtcvs.2018.01.087

69. Pirola S, Mastroiacovo G, Arlati FG, Mostardini G, Bonomi A, Penza E et al. Single Center Five Years’ Experience of Ozaki Procedure: Midterm Follow-up. The Annals of Thoracic Surgery. 2021;111(6):1937–43. DOI: 10.1016/j.athoracsur.2020.08.039

70. Chernov I.I., Enginoev S.T., Komarov R.N., Bazylev V.V., Tarasov D.G., Kadyraliev K.B. et al. Short-term outcomes of Ozaki procedure: a multicenter study. Russian Journal of Cardiology. 2020;25(S4):13–8. DOI: 10.15829/1560-4071-2020-4157

71. Tissot-Dupont H, Casalta JP, Gouriet F, Hubert S, Salaun E, Habib G et al. International experts’ practice in the antibiotic therapy of infective endocarditis is not following the guidelines. Clinical Microbiology and Infection. 2017;23(10):736–9. DOI: 10.1016/j.cmi.2017.03.007

72. Dajani AS, Taubert KA, Wilson W, Bolger AF, Bayer A, Ferrieri P et al. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. JAMA. 1997;277(22):1794–801. PMID: 9178793

73. Wilson WR, Gewitz M, Lockhart PB, Bolger AF, DeSimone DC, Kazi DS et al. Prevention of Viridans Group Streptococcal Infective Endocarditis: A Scientific Statement From the American Heart Association. Circulation. 2021;143(20):963–78. DOI: 10.1161/CIR.0000000000000969

74. Botelho-Nevers E, Thuny F, Casalta JP, Richet H, Gouriet F, Collart F et al. Dramatic Reduction in Infective Endocarditis–Related Mortality With a Management-Based Approach. Archives of Internal Medicine. 2009;169(14):1290–8. DOI: 10.1001/archinternmed.2009.192

75. Chirillo F, Scotton P, Rocco F, Rigoli R, Borsatto F, Pedrocco A et al. Impact of a Multidisciplinary Management Strategy on the Outcome of Patients With Native Valve Infective Endocarditis. The American Journal of Cardiology. 2013;112(8):1171–6. DOI: 10.1016/j.amjcard.2013.05.060

76. Wahadat AR, Tanis W, Galema TW, Swart LE, van Leeuwen WJ, Verkaik NJ et al. The impact of the multidisciplinary Endocarditis Team on the management of infective endocarditis. Netherlands Heart Journal. 2023;31(1):29–35. DOI: 10.1007/s12471-022-01707-6